324 related articles for article (PubMed ID: 7647332)
1. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Li S; Lévesque C; Geng CS; Yan X; Labrie F
Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats.
Luo S; Stojanovic M; Labrie C; Labrie F
Int J Cancer; 1997 Nov; 73(4):580-6. PubMed ID: 9389575
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Labrie F; Li S; Labrie C; Lévesque C; Mérand Y
Breast Cancer Res Treat; 1995 Mar; 33(3):237-44. PubMed ID: 7749151
[TBL] [Abstract][Full Text] [Related]
4. Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat: a model of postmenopausal breast cancer.
Li S; Martel C; Dauvois S; Bélanger A; Labrie F
Endocrinology; 1994 Mar; 134(3):1352-7. PubMed ID: 8119175
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.
Luo S; Sourla A; Labrie C; Bélanger A; Labrie F
Endocrinology; 1997 Oct; 138(10):4435-44. PubMed ID: 9322961
[TBL] [Abstract][Full Text] [Related]
8. Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavone.
Ritter CL; Prigge WF; Reichert MA; Malejka-Giganti D
Can J Physiol Pharmacol; 2001 Jun; 79(6):519-32. PubMed ID: 11430590
[TBL] [Abstract][Full Text] [Related]
9. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.
Couture P; Thériault C; Simard J; Labrie F
Endocrinology; 1993 Jan; 132(1):179-85. PubMed ID: 8380373
[TBL] [Abstract][Full Text] [Related]
11. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
13. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice.
Dauvois S; Geng CS; Lévesque C; Mérand Y; Labrie F
Cancer Res; 1991 Jun; 51(12):3131-5. PubMed ID: 2039992
[TBL] [Abstract][Full Text] [Related]
14. Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat.
Dauvois S; Spinola PG; Labrie F
Eur J Cancer Clin Oncol; 1989 May; 25(5):891-7. PubMed ID: 2525471
[TBL] [Abstract][Full Text] [Related]
15. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts.
Couillard S; Labrie C; Bélanger A; Candas B; Pouliot F; Labrie F
J Natl Cancer Inst; 1998 May; 90(10):772-8. PubMed ID: 9605648
[TBL] [Abstract][Full Text] [Related]
16. Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050).
Luo S; Labrie C; Bélanger A; Candas B; Labrie F
Breast Cancer Res Treat; 1998 May; 49(1):1-11. PubMed ID: 9694606
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibitory activity of a new antiestrogen, RU 16 117, on the development and growth of DMBA-induced rat mammary adenocarcinoma.
Labrie F; Kelly PA; Asselin J; Raynaud JP
Recent Results Cancer Res; 1976; (57):109-20. PubMed ID: 827798
[TBL] [Abstract][Full Text] [Related]
18. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020).
Nguyen BL; Chetrite G; Pasqualini JR
Breast Cancer Res Treat; 1995 May; 34(2):139-46. PubMed ID: 7647331
[TBL] [Abstract][Full Text] [Related]
19. Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat.
Martel C; Sourla A; Pelletier G; Labrie C; Fournier M; Picard S; Li S; Stojanovic M; Labrie F
J Endocrinol; 1998 Jun; 157(3):433-42. PubMed ID: 9691976
[TBL] [Abstract][Full Text] [Related]
20. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
